BioWa, Inc. announced that it has expanded the license agreement with Genentech, Inc. providing Genentech additional access to BioWa’s POTELLIGENT® Technology for the research and development of select antibodies for potential therapeutic applications
PRINCETON, NJ, USA | March 3, 2008 | BioWa, Inc. announced today that it has expanded the license agreement with Genentech, Inc. providing Genentech additional access to BioWa’s POTELLIGENT® Technology for the research and development of select antibodies for potential therapeutic applications that require enhancement of antibody-dependent cellular cytotoxicity (ADCC).
“BioWa is pleased to extend this license with Genentech, which is a market leader in the field of antibody therapeutics,” commented Dr. Masamichi Koike, President and CEO of BioWa. “We feel this alliance will strongly aid in the development of more effective targeted treatments for cancer and other diseases.”
Under the terms of the expanded license agreement, BioWa will grant to Genentech commercial rights to research, develop, manufacture and commercialize antibodies utilizing POTELLIGENT® Technology for an additional number of targets. In return, BioWa will receive milestone payments and royalties on products developed by Genentech. Additional terms were not disclosed.
About POTELLIGENT® Technology
POTELLIGENT® Technology improves potency and efficacy of antibody therapeutics, by enhancing ADCC, one of the major mechanisms of action for antibody therapeutics. POTELLIGENT® Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout CHO cell line as a production cell. Research shows that POTELLIGENT® Technology dramatically enhances ADCC activity of an antibody in vitro, and significantly increases potency and efficacy of the antibody in vivo.
About BioWa, Inc.
BioWa is a wholly owned subsidiary of Kyowa Hakko Kogyo Co., Ltd. (TSE:4151), Japan’s leading pharmaceutical and largest biotech company, and is the exclusive worldwide licensor of AccretaMab™ platform. AccretaMab™ platform consists of POTELLIGENT® and COMPLEGENT™ Technologies, creating a superior antibody molecule with enhanced ADCC and CDC activities. BioWa is offering POTELLIGENT® and COMPLEGENT™ Technologies to partners under a license to maximize the value of these technologies. In addition, BioWa is focused on development of ADCC/CDC enhanced monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases. Both BioWa and Kyowa have POTELLIGENT® antibody products at various clinical stages. For more information about BioWa, visit its web site at www.biowa.com.
POTELLIGENT®, COMPLEGENT™, and AccretaMab™ are the trademarks of Kyowa Hakko Kogyo Co.
SOURCE: BIOWA
Post Views: 104
BioWa, Inc. announced that it has expanded the license agreement with Genentech, Inc. providing Genentech additional access to BioWa’s POTELLIGENT® Technology for the research and development of select antibodies for potential therapeutic applications
PRINCETON, NJ, USA | March 3, 2008 | BioWa, Inc. announced today that it has expanded the license agreement with Genentech, Inc. providing Genentech additional access to BioWa’s POTELLIGENT® Technology for the research and development of select antibodies for potential therapeutic applications that require enhancement of antibody-dependent cellular cytotoxicity (ADCC).
“BioWa is pleased to extend this license with Genentech, which is a market leader in the field of antibody therapeutics,” commented Dr. Masamichi Koike, President and CEO of BioWa. “We feel this alliance will strongly aid in the development of more effective targeted treatments for cancer and other diseases.”
Under the terms of the expanded license agreement, BioWa will grant to Genentech commercial rights to research, develop, manufacture and commercialize antibodies utilizing POTELLIGENT® Technology for an additional number of targets. In return, BioWa will receive milestone payments and royalties on products developed by Genentech. Additional terms were not disclosed.
About POTELLIGENT® Technology
POTELLIGENT® Technology improves potency and efficacy of antibody therapeutics, by enhancing ADCC, one of the major mechanisms of action for antibody therapeutics. POTELLIGENT® Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout CHO cell line as a production cell. Research shows that POTELLIGENT® Technology dramatically enhances ADCC activity of an antibody in vitro, and significantly increases potency and efficacy of the antibody in vivo.
About BioWa, Inc.
BioWa is a wholly owned subsidiary of Kyowa Hakko Kogyo Co., Ltd. (TSE:4151), Japan’s leading pharmaceutical and largest biotech company, and is the exclusive worldwide licensor of AccretaMab™ platform. AccretaMab™ platform consists of POTELLIGENT® and COMPLEGENT™ Technologies, creating a superior antibody molecule with enhanced ADCC and CDC activities. BioWa is offering POTELLIGENT® and COMPLEGENT™ Technologies to partners under a license to maximize the value of these technologies. In addition, BioWa is focused on development of ADCC/CDC enhanced monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases. Both BioWa and Kyowa have POTELLIGENT® antibody products at various clinical stages. For more information about BioWa, visit its web site at www.biowa.com.
POTELLIGENT®, COMPLEGENT™, and AccretaMab™ are the trademarks of Kyowa Hakko Kogyo Co.
SOURCE: BIOWA
Post Views: 104
